BVT Call 42 BMY 20.12.2024/ DE000VD6N6R4 /
2024-11-12 7:55:01 PM | Chg.-0.050 | Bid9:55:54 PM | Ask9:55:54 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
1.680EUR | -2.89% | - Bid Size: - |
- Ask Size: - |
Bristol Myers Squibb... | 42.00 USD | 2024-12-20 | Call |
GlobeNewswire
09-02
CSE Announces its 2024 Sustainability & ESG Leadership Summit at NYC's One World Trade Center
GlobeNewswire
08-30
Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
08-28
Hematologists Highlight Ongoing Challenges in Sickle Cell Disease and Thalassemia Amidst Promising A...
GlobeNewswire
08-22
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive ...
GlobeNewswire
08-15
Abata Therapeutics Announces Strategic Investment from Bristol Myers Squibb Supporting Advancement o...
GlobeNewswire
08-12
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in C...
Newsfile Corp
08-12
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
GlobeNewswire
08-08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-07
Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Diseas...
GlobeNewswire
08-05
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
GlobeNewswire
08-01
Outpace Bio Announces $144M Oversubscribed Series B Financing to Advance AI-powered Cell Therapies i...
GlobeNewswire
08-01
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
07-31
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Boar...
GlobeNewswire
07-25
Purple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price Rule
GlobeNewswire
07-24
Prota Therapeutics Strengthens Board with Appointment of Global Biotech Expert Patrick Machado
GlobeNewswire
07-20
NCLA Asks Third Circuit to Rule Against HHS’s Coercive Medicare Drug Price ‘Negotiation’ Program